Microglial Phagocytosis and AB-Mediated Neurotoxicity
About the Research Project
Program
Award Type
Standard
Award Amount
$160,326
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
A2000052
Summary
Microglia are specialized phagocytic cells of the central nervous system that engulf or phagocytize material and also mediate inflammatory responses. Based on these properties, they are thought to play a role in AD, especially since cell culture studies have shown that they can also phagocytize Ab. However, there is also some evidence that microglia do not effectively break down internalized Ab. This may lead to chronic activation and contribute to the progression of the disease. Dr. Webster is trying to determine whether the ingestion of Ab by brain cells causes the release of neurotoxic inflammatory molecules called cytokines. The production of oxygen-free radicals is also being monitored, and the production of both cytokines and free radicals will be correlated with the amount of undegraded Ab present inside the microglial cells. This information is important because some of the therapies currently being explored, such as an Ab vaccine, are predicated on the assumption that increased uptake of Ab by microglia will alleviate disease. However, if Ab activates microglia inflammatory responses, then the strategy of stimulating uptake could actually worsen the disease.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD